Advertisement
STE vs XRAY
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is STE is a Hold and XRAY is a Hold.
STE's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for STE turned positive on September 29, 2026. Looking at past instances where STE's MACD turned positive, the stock continued to rise in 28 of 47 cases over the following month. The odds of a continued upward trend are 60%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where STE's RSI Indicator exited the oversold zone, 18 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 58%.
The Momentum Indicator moved above the 0 level on October 08, 2026. You may want to consider a long position or call options on STE as a result. In 53 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 55%.
Following a +3.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where STE advanced for three days, in 152 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 48%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The 10-day moving average for STE crossed bearishly below the 50-day moving average on September 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 59%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 57%.
STE broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for STE entered a downward trend on September 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.855) is normal, around the industry mean (10.930). P/E Ratio (25.795) is within average values for comparable stocks, (100.178). Projected Growth (PEG Ratio) (1.760) is also within normal values, averaging (11.052). STE has a moderately high Dividend Yield (0.012) as compared to the industry average of (0.002). P/S Ratio (3.423) is also within normal values, averaging (40.124).
The Tickeron Seasonality Score of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. STE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 66 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 78 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 88 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
XRAY sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for XRAY moved below the 200-day moving average on September 25, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XRAY as a result. In 71 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XRAY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
The Aroon Indicator for XRAY entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for XRAY just turned positive on October 09, 2026. Looking at past instances where XRAY's MACD turned positive, the stock continued to rise in 31 of 54 cases over the following month. The odds of a continued upward trend are 57%.
Following a +3.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where XRAY advanced for three days, in 172 of 297 cases, the price rose further within the following month. The odds of a continued upward trend are 58%.
XRAY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.369) is normal, around the industry mean (5.011). P/E Ratio (19.231) is within average values for comparable stocks, (163.451). Projected Growth (PEG Ratio) (0.601) is also within normal values, averaging (4.456). XRAY's Dividend Yield (0.034) is considerably higher than the industry average of (0.005). P/S Ratio (0.557) is also within normal values, averaging (56.074).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. XRAY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XRAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
STE | XRAY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 21 | 56 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 8 Undervalued | 2 Undervalued | |
PROFIT vs RISK RATING 1..100 | 88 | 100 | |
SMR RATING 1..100 | 66 | 97 | |
PRICE GROWTH RATING 1..100 | 48 | 65 | |
P/E GROWTH RATING 1..100 | 78 | 81 | |
SEASONALITY SCORE 1..100 | 32 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
XRAY's Valuation (2) in the Medical Specialties industry is in the same range as STE (8). This means that XRAY’s stock grew similarly to STE’s over the last 12 months.
STE's Profit vs Risk Rating (88) in the Medical Specialties industry is in the same range as XRAY (100). This means that STE’s stock grew similarly to XRAY’s over the last 12 months.
STE's SMR Rating (66) in the Medical Specialties industry is in the same range as XRAY (97). This means that STE’s stock grew similarly to XRAY’s over the last 12 months.
STE's Price Growth Rating (48) in the Medical Specialties industry is in the same range as XRAY (65). This means that STE’s stock grew similarly to XRAY’s over the last 12 months.
STE's P/E Growth Rating (78) in the Medical Specialties industry is in the same range as XRAY (81). This means that STE’s stock grew similarly to XRAY’s over the last 12 months.
| STE | XRAY | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 58% | 1 day ago 57% |
| Stochastic ODDS (%) | 1 day ago 54% | 1 day ago 46% |
| Momentum ODDS (%) | 1 day ago 55% | 6 days ago 76% |
| MACD ODDS (%) | 1 day ago 60% | 1 day ago 57% |
| TrendWeek ODDS (%) | 1 day ago 51% | 1 day ago 74% |
| TrendMonth ODDS (%) | 1 day ago 47% | 1 day ago 74% |
| Advances ODDS (%) | 3 days ago 48% | 6 days ago 58% |
| Declines ODDS (%) | 13 days ago 57% | 1 day ago 74% |
| BollingerBands ODDS (%) | 1 day ago 61% | 1 day ago 62% |
| Aroon ODDS (%) | 1 day ago 34% | 1 day ago 74% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
STE’s FA Score shows that 1 FA rating(s) are green while XRAY’s FA Score has 1 green FA rating(s).
- STE’s FA Score: 1 green, 4 red.
- XRAY’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
STE’s TA Score shows that 4 TA indicator(s) are bullish while XRAY’s TA Score has 5 bullish TA indicator(s).
- STE’s TA Score: 4 bullish, 5 bearish.
- XRAY’s TA Score: 5 bullish, 4 bearish.
Price Growth
STE (@Medical/Nursing Services) experienced а +4.37% price change this week, while XRAY (@Pharmaceuticals: Other) price change was -0.18% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -3.54%. For the same industry, the average monthly price growth was -6.26%, and the average quarterly price growth was -14.18%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.08%. For the same industry, the average monthly price growth was -4.76%, and the average quarterly price growth was +4.14%.
Reported Earning Dates
STE is expected to report earnings on Nov 11, 2026.
XRAY is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Medical/Nursing Services (-3.54% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (-1.08% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
STE and
Correlation & Price change
A.I.dvisor indicates that over the last year, STE has been loosely correlated with SYK. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if STE jumps, then SYK could also see price increases.